GT Biopharma, Inc. announced that it has entered into agreements to exercise existing warrants for a total of 302,069 shares of its common stock at an exercise price of $4.35, which were issued in ...

Shares of GT Biopharma, Inc. surged more than 21% on Tuesday before slipping after-hours as investors reacted to the company's unexpected shift in its financing strategy. The announcement sent 24 ...

EST GT Biopharma (GTBP) files to sell 625,283 shares of common stock for holdersDiscover the Best Stocks and Maximize Your Portfolio: See ...

GT Biopharma (NASDAQ:GTBP) just reported results for the fourth quarter of 2023. GT Biopharma reported earnings per share of -$2.14. This was above the analyst estimate for EPS of -$2.70.

Dr. Miller will speak to the mechanisms by which tri-specific engagers enhance NK cell activity, their unique ability to work synergistically with NK cells to improve cytotoxicity and increase ...

GT Biopharma, Inc. SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on ...

SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics ...

GT Biopharma holds an exclusive worldwide license agreement with the University of Minnesota, strengthening its collaboration and potential for future innovations using TriKE® technology.

SAN FRANCISCO, CALIFORNIA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative ...

Get Our Latest Stock Report on GT Biopharma GT Biopharma Price Performance NASDAQ:GTBP opened at $2.38 on Friday. GT Biopharma has a 12-month low of $1.72 and a 12-month high of $10.66. The firm ...

GT Biopharma, Inc. SAN FRANCISCO, CALIFORNIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on ...

GTB-3650, GT Biopharma’s wholly owned second-generation TriKE, is currently being evaluated in a Phase 1 dose escalation study in patients with hematological malignancies. Enrollment is ...